mefruside has been researched along with Prostatic Neoplasms in 1 studies
Mefruside: A benzene-sulfonamide-furan. It is used as a diuretic that affects the concentrating ability of the KIDNEY, increases SODIUM CHLORIDE excretion, but may not spare POTASSIUM. It inhibits CARBONIC ANHYDRASES and may increase the blood URIC ACID level.
Prostatic Neoplasms: Tumors or cancer of the PROSTATE.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bartsch, W | 1 |
| Horst, HJ | 1 |
| Becker, H | 1 |
| Nehse, G | 1 |
1 trial available for mefruside and Prostatic Neoplasms
| Article | Year |
|---|---|
Sex hormone binding globulin binding capacity, testosterone, 5alpha-dihydrotestosterone, oestradiol and prolactin in plasma of patients with prostatic carcinoma under various types of hormonal treatment.
Topics: Chorionic Gonadotropin; Clinical Trials as Topic; Cyproterone; Diethylstilbestrol; Dihydrotestostero | 1977 |